Khalid A Abdelhalim, Yanzhe Wang, Asadoor Amirkhani Namagerdi, Narjes Alfuraiji, David Mburu, Hatim A Hassan
{"title":"Gut Oxalate Transport and Gut Microbiome as Potential Therapeutic Targets for Hyperoxaluria and Hyperoxalemia: Implications for Related Human Disease.","authors":"Khalid A Abdelhalim, Yanzhe Wang, Asadoor Amirkhani Namagerdi, Narjes Alfuraiji, David Mburu, Hatim A Hassan","doi":"10.1016/j.mayocp.2026.04.020","DOIUrl":"https://doi.org/10.1016/j.mayocp.2026.04.020","url":null,"abstract":"<p><p>Besides kidney stones (KS), oxalate potentially contributes to chronic kidney disease (CKD) and its progression, CKD- and end stage kidney disease (ESKD)-associated cardiovascular diseases, and poor kidney transplant survival. KS affect about 1 in 5 men and 1 in 11 women and the recurrence rate remains high (50% in 5 years and up to 80% in 10-20 years), reflecting that current interventions are inadequate, and novel therapies are needed. 70-80% of KS are composed of calcium oxalate and small increases in urine oxalate enhance the KS risk. The gastrointestinal tract (gut) plays a major role in oxalate homeostasis by acting as a site for oxalate absorption and secretion. Therefore, the gut potentially represents a novel therapeutic pathway for body oxalate elimination. Strategies aiming at reducing the gut's ability to absorb oxalate and/or enhancing its ability to secrete oxalate can lead to decreased plasma and urinary oxalate levels and therefore can serve as novel approaches for the prevention and/or treatment of hyperoxalemia and hyperoxaluria. Humans lack oxalate metabolizing enzymes, and they rely on gut bacteria referred to as oxalate-degrading bacteria (oxalobiome) for gut oxalate degradation. This limits net gut oxalate absorption, thereby helping with maintaining normal oxalate homeostasis. This review focuses on the role of gut oxalate transport and gut microbiome in overall oxalate homeostasis and how they can be therapeutically targeted. Importantly, the majority of evidence for gut oxalate transport is derived from animal studies, but the relevance of these findings to human gut oxalate transport remains to be established.</p>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rickey E Carter, Mikolaj A Wieczorek, Laura M Pacheco-Spann, FeiFei Li, Jingjing Michele Dougherty, Patrick W Johnson, Benedict Wenzel, Mahul Pandey, Archismita Dalal, Enrique Solano, Karahan Yilmazer, Surjo R Soekadar, Kent R Thielen, Charles J Bruce
{"title":"Hybrid Quantum-Classical Model That Combines Spatial-Temporal EEG and Digitized Counterdiabatic Quantum Features for Motor Imagery Classification.","authors":"Rickey E Carter, Mikolaj A Wieczorek, Laura M Pacheco-Spann, FeiFei Li, Jingjing Michele Dougherty, Patrick W Johnson, Benedict Wenzel, Mahul Pandey, Archismita Dalal, Enrique Solano, Karahan Yilmazer, Surjo R Soekadar, Kent R Thielen, Charles J Bruce","doi":"10.1016/j.mayocp.2026.04.017","DOIUrl":"https://doi.org/10.1016/j.mayocp.2026.04.017","url":null,"abstract":"<p><strong>Objective: </strong>To develop a quantum-feature enhanced algorithm for motor imagery (MI) classification using electroencephalogram (EEG) waveforms.</p><p><strong>Patients and methods: </strong>Data were obtained from a published, de-identified data set. Fifty participants were available for model training and one participant's data was reserved for external evaluation. Each participant underwent 600 MI task cues over three sessions associated with four-second, 58-lead EEG waveforms. Our approach used a spatial-temporal deep learning architecture to reduce the raw waveforms down to a 24-dimension feature set for digitized counterdiabatic quantum feature extraction. The final classifier combined the deep learning prediction with the quantum features to provide an overall MI prediction weighting the quantum features more heavily when the spatial-temporal deep learning model was uncertain.</p><p><strong>Results: </strong>All 51 participants were right-handed and 34 (67%) were male. The mean (SD) age was 23 (2.2) years with a range 17 and 30 years of age. The evaluation participant was a 22-year-old male. The classification accuracy in the evaluation participant was 88.8% (533/600, 95% CI: 86.0% to 91.2%) with an AUROC of 0.962 (95% CI: 0.948 to 0.976). The classification accuracy for the entire set of 51 participants was 89.8% (27,478/30,590; 95% CI: 87.5% to 92.2%) with an AUROC of 0.970 (95% CI: 0.956 to 0.980). Model performance improved with age (Spearman's rho = 0.35, p=0.012).</p><p><strong>Conclusion: </strong>A combination of deep learning feature extraction enriched with quantum features resulted in robust classification of MI EEG waveforms setting a foundation for further study of quantum computing in health care.</p>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mayo Clinic proceedingsPub Date : 2026-05-01Epub Date: 2026-03-28DOI: 10.1016/j.mayocp.2026.02.004
Justin M. Chan MD, Pahresah L. Roomiany MD, MS, FACP, Halima A. Naeem MD, Carter W. Hruby MD
{"title":"Unexpected Breakdown: Influenza A–Associated Rhabdomyolysis in the 2024-2025 Season","authors":"Justin M. Chan MD, Pahresah L. Roomiany MD, MS, FACP, Halima A. Naeem MD, Carter W. Hruby MD","doi":"10.1016/j.mayocp.2026.02.004","DOIUrl":"10.1016/j.mayocp.2026.02.004","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"101 5","pages":"Pages 886-887"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mayo Clinic proceedingsPub Date : 2026-05-01Epub Date: 2026-01-21DOI: 10.1016/j.mayocp.2025.10.016
Benjamin D. Boudreaux PhD , Chang Xu MA , Maria A. Serafini BS , Erin E. Dooley PhD , Bjoern Hornikel PhD , Alexandra Munson MPH , Ari Shechter PhD , Marie-Pierre St Onge PhD , Priya Palta PhD , Kelley Pettee Gabriel PhD , Keith M. Diaz PhD
{"title":"Achieving Guidelines Within a 24-Hour Movement Paradigm and Risk of Mortality in US Adults","authors":"Benjamin D. Boudreaux PhD , Chang Xu MA , Maria A. Serafini BS , Erin E. Dooley PhD , Bjoern Hornikel PhD , Alexandra Munson MPH , Ari Shechter PhD , Marie-Pierre St Onge PhD , Priya Palta PhD , Kelley Pettee Gabriel PhD , Keith M. Diaz PhD","doi":"10.1016/j.mayocp.2025.10.016","DOIUrl":"10.1016/j.mayocp.2025.10.016","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the association of meeting the 24-hour movement guidelines and risk of cardiovascular disease (CVD) and all-cause mortality in a national representative sample of US adults.</div></div><div><h3>Methods</h3><div>The study included US adults (N=41,930) from the 2005 and 2010 waves of the National Health Interview Survey. Self-reported moderate to vigorous physical activity (guideline: ≥150 minutes per week of moderate, ≥75 minutes per week of vigorous, or equivalent of both), total sitting time (guideline: leisure sedentary time <8 hours per day for nonworking adults; <4 hours per day for working adults), and total sleep duration (guideline: 7 to 9 hours per day). All-cause and CVD mortality data were obtained from the National Death Index.</div></div><div><h3>Results</h3><div>During a median follow-up of 9.9 years, 3786 participants died of all causes; of those, 835 died of CVD. Meeting a greater number of 24-hour movement guidelines was associated with lower all-cause mortality risk (hazard ratios, 0.81 [95% CI, 0.71 to 0.93], 0.75 [95% CI, 0.65 to 0.87], and 0.63 [95% CI, 0.53 to 0.75] for meeting 1, 2, or 3 guidelines, respectively) vs meeting 0 guidelines (<em>P</em><sub>trend</sub><.001). Meeting a greater number of 24-hour movement guidelines was associated with a reduced CVD mortality risk (hazard ratios, 0.93 [95% CI, 0.69 to 1.25], 0.90 [95% CI, 0.67 to 1.20], and 0.53 [95% CI, 0.37 to 0.76] for meeting 1, 2, or 3 guidelines, respectively) vs meeting 0 guidelines (<em>P</em><sub>trend</sub><.001).</div></div><div><h3>Conclusion</h3><div>A dose-response relationship was observed for participants meeting all 3 guidelines, with a 37% and 47% reduced risk of all-cause mortality and CVD mortality, respectively. These findings support promoting a healthy 24-hour behavior pattern to reduce mortality risk.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"101 5","pages":"Pages 754-766"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146011174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mayo Clinic proceedingsPub Date : 2026-05-01Epub Date: 2026-03-28DOI: 10.1016/j.mayocp.2026.01.031
Sandra L. Kane-Gill PharmD, MSc , Erin F. Barreto PharmD, PhD , Alexander H. Flannery PharmD, PhD , Todd A. Miano PharmD, PhD , Raghavan Murugan MD, MS , Tezcan Ozrazgat-Baslanti PhD , Azra Bihorac MD, MS , John A. Kellum MD , MEnD-AKI Study and Acute Kidney Intervention and Pharmacotherapy Group
{"title":"Perspective: Taxonomy of Kidney Diseases and Disorders Related to Nephrotoxic Drug Exposure in Hospitalized Patients","authors":"Sandra L. Kane-Gill PharmD, MSc , Erin F. Barreto PharmD, PhD , Alexander H. Flannery PharmD, PhD , Todd A. Miano PharmD, PhD , Raghavan Murugan MD, MS , Tezcan Ozrazgat-Baslanti PhD , Azra Bihorac MD, MS , John A. Kellum MD , MEnD-AKI Study and Acute Kidney Intervention and Pharmacotherapy Group","doi":"10.1016/j.mayocp.2026.01.031","DOIUrl":"10.1016/j.mayocp.2026.01.031","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"101 5","pages":"Pages 716-724"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mayo Clinic proceedingsPub Date : 2026-05-01Epub Date: 2026-03-05DOI: 10.1016/j.mayocp.2025.11.020
Fa Shen MS , Hao-Yu Liu BS , Yu-Yang Liu MS , Jia-Qi Yang BS , Li-Wen Zhang BS , Qian-Man Li BS , Lu Liu BS , Ting-Ting Gong MD, PhD , Qi-Jun Wu MD, PhD , Shan-Yan Gao MD, PhD
{"title":"Accelerometer-Derived Physical Activity Associated With Incidence and Progression Trajectory of Cardiometabolic Multimorbidity","authors":"Fa Shen MS , Hao-Yu Liu BS , Yu-Yang Liu MS , Jia-Qi Yang BS , Li-Wen Zhang BS , Qian-Man Li BS , Lu Liu BS , Ting-Ting Gong MD, PhD , Qi-Jun Wu MD, PhD , Shan-Yan Gao MD, PhD","doi":"10.1016/j.mayocp.2025.11.020","DOIUrl":"10.1016/j.mayocp.2025.11.020","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the associations between physical activity (PA) and the transition from healthy status to first cardiometabolic disease (FCMD), subsequently to cardiometabolic multimorbidity (CMM), and further to death.</div></div><div><h3>Patients and Methods</h3><div>Objectively measured PA was derived from wrist-worn accelerometer data collected during 7 days in a separate cohort of 59,161 participants during 2013 to 2015. Cardiometabolic multimorbidity was defined as the occurrence of at least 2 cardiometabolic diseases including type 2 diabetes, ischemic heart disease, and stroke. Multistate models were used to examine the impact of PA on the incidence and progression trajectory of CMM.</div></div><div><h3>Results</h3><div>During a median 7.9 years of follow-up, FCMD developed in 4074 individuals, CMM developed in 295, and 2893 died in the accelerometer-derived cohort. Performing guideline-adherent moderate-intensity physical activity (MPA; 150-300 min/wk) was related to a 29% lower risk of FCMD (hazard ratio [HR], 0.71 [0.62 to 0.81]) and a 40% lower risk of CMM (HR, 0.60 [0.39 to 0.93]). The strength of the association of MPA with the transition from healthy baseline to FCMD was greater than that of the transition from FCMD to CMM, with HRs (95% CIs) per 244.7 min/wk increase of 0.75 (0.71 to 0.80) and 0.92 (0.87 to 0.98), respectively. On dividing FCMD into 3 specific cardiometabolic diseases, there were comparable trends of MPA on the disease-specific transitions from healthy baseline to FCMD and subsequent CMM.</div></div><div><h3>Conclusion</h3><div>Physical activity played comparable roles in transitions from healthy baseline to FCMD and then to CMM. These findings suggest that improving PA is a potential strategy for preventing CMM development.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"101 5","pages":"Pages 767-781"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147355530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}